Résultats de la recherche - Min Ning
- Résultat(s) 1 - 19 résultats de 19
-
1
-
2
-
3
-
4
-
5
-
6
-
7
FXR Signaling-Mediated Bile Acid Metabolism Is Critical for Alleviation of Cholesterol Gallstones by <i>Lactobacillus</i> Strains par Xin Ye, Dan Huang, Zhixia Dong, Xiaoxin Wang, Min Ning, Jie Xia, Shuang Shen, Shangong Wu, Yan Shi, Jingjing Wang, Xinjian Wan
Publié 2022Artigo -
8
Efficacy of 3 years of adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance par Song, Min-Ning, Hong, Mei-Zhu, Luo, Dan-Qing, Huang, Wen-Qi, Min, Feng, Fan, Rong-Hua, Wu, Wei-Bing, Zhang, Li
Publié 2012Texte -
9
Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy par Wilfred D. Stein, James L. Gulley, Jeff Schlom, Ravi A. Madan, William L. Dahut, William D. Figg, Yang‐Min Ning, Phil M. Arlen, Doug Price, Susan E. Bates, Tito Fojo
Publié 2010Artigo -
10
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy par Yang‐Min Ning, Daniel L. Suzman, V. Ellen Maher, Lijun Zhang, Shenghui Tang, Tiffany K. Ricks, Todd R. Palmby, Wentao Fu, Qi Liu, Kirsten B. Goldberg, Geoffrey Kim, Richard Pazdur
Publié 2017Artigo -
11
Precise prediction model and simplified scoring system for sustained combined response to interferon-α par Mao, Qian-Guo, Pan, Jin-Shui, Fang, Kuang-Nan, Zhang, Ru-Mian, Hong, Qing-Yang, Song, Min-Ning, Zhu, Jian-Ping, Huang, Wen-Qi, Chen, Li-Min, Hong, Mei-Zhu
Publié 2010Texte -
12
Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents par Jeanny B. Aragon‐Ching, Yang‐Min Ning, Clara C. Chen, Lea Latham, Jean-Pierre Guadagnini, James L. Gulley, Philip M. Arlen, James R. Wright, Howard L. Parnes, William D. Figg, William L. Dahut
Publié 2009Artigo -
13
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy par Daniel L. Suzman, Sundeep Agrawal, Yang-Min Ning, V. Ellen Maher, Laura L. Fernandes, Stella Karuri, Shenghui Tang, Rajeshwari Sridhara, Jason Schroeder, Kirsten B. Goldberg, Amna Ibrahim, Amy E. McKee, Richard Pazdur, Julia A. Beaver
Publié 2018Artigo -
14
Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval... par Yang‐Min Ning, William F. Pierce, V. Ellen Maher, Stella Karuri, Shenghui Tang, Haw-Jyh Chiu, Todd R. Palmby, Jeanne Fourie Zirkelbach, Dhananjay Marathe, Nitin Mehrotra, Qi Liu, Debasis Ghosh, Christy L. Cottrell, John K. Leighton, Rajeshwari Sridhara, Amna Ibrahim, Robert Justice, Richard Pazdur
Publié 2013Artigo -
15
Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer par Yang-Min Ning, James L. Gulley, Philip M. Arlen, Sukyung Woo, Seth M. Steinberg, James R. Wright, Howard L. Parnes, Jane B. Trepel, Min-Jung Lee, Yeong Sang Kim, Haihao Sun, Ravi A. Madan, Lea Latham, Elizabeth C. Jones, Clara C. Chen, William D. Figg, William L. Dahut
Publié 2010Artigo -
16
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells par Johanny Tonos De Leon, Aki Iwai, Clémentine Féau, Yenni A. Garcia, Heather A. Balsiger, Cheryl L. Storer, Raquel M. Suro, Kristine M. Garza, Sunmin Lee, Yeong Sang Kim, Yu Chen, Yang-Min Ning, Daniel L. Riggs, Robert J. Fletterick, R. Kiplin Guy, Jane B. Trepel, Leonard Μ. Neckers, Marc B. Cox
Publié 2011Artigo -
17
FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation par Geoffrey Kim, Amy E. McKee, Yang‐Min Ning, Maitreyee Hazarika, Marc R. Theoret, John R. Johnson, Qiang Casey Xu, Shenghui Tang, Rajeshwari Sridhara, Xiaoping Jiang, Kun He, Donna Roscoe, W. David McGuinn, Whitney S. Helms, Anne‐Marie Russell, Sarah Pope Miksinski, Jeanne Fourie Zirkelbach, Justin Earp, Qi Liu, Amna Ibrahim, Robert Justice, Richard Pazdur
Publié 2014Revisão -
18
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial par Andrea B. Apolo, Rosa Nadal, Yusuke Tomita, Nicole N. Davarpanah, Lisa M. Cordes, Seth M. Steinberg, Liang Cao, Howard L. Parnes, Rene Costello, Maria J. Merino, Les Folio, Liza Lindenberg, Mark Raffeld, Jeffrey Lin, Min-Jung Lee, Sunmin Lee, Sylvia V. Alarcon, Akira Yuno, Nancy A. Dawson, Kimaada Allette, Arpita Singha Roy, Dinuka De Silva, Molly M. Lee, Tristan M. Sissung, William D. Figg, Piyush K. Agarwal, James R. Wright, Yang‐Min Ning, James L. Gulley, William L. Dahut, Donald P. Bottaro, Jane B. Trepel
Publié 2020Artigo -
19
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors par Andrea B. Apolo, Rosa Nadal, Daniel M. Girardi, Scot A. Niglio, Lisa Ley, Lisa M. Cordes, Seth M. Steinberg, Olena Sierra Ortiz, Jacqueline Cadena, Carlos Guerrero Díaz, Marissa Mallek, Nicole N. Davarpanah, Rene Costello, Jane B. Trepel, Min-Jung Lee, Maria J. Merino, Mohammadhadi Bagheri, Paul Monk, William D. Figg, James L. Gulley, Piyush K. Agarwal, Vladimir Valera, Heather J. Chalfin, Jennifer Jones, Howard Streicher, James R. Wright, Yang‐Min Ning, Howard L. Parnes, William L. Dahut, Donald P. Bottaro, Primo N. Lara, Biren Saraiya, Sumanta K. Pal, Mark N. Stein, Amir Mortazavi
Publié 2020Artigo
Outils de recherche:
Sujets similaires
Medicine
Internal medicine
Cancer
Oncology
Biochemistry
Biology
Chemotherapy
Endocrinology
Gene
Prostate cancer
Receptor
Adverse effect
Bladder cancer
Chemistry
Clinical endpoint
Clinical trial
Metastatic Urothelial Carcinoma
Urothelial carcinoma
Cancer research
Cell biology
Docetaxel
Gastroenterology
Immunotherapy
Urology
Androgen deprivation therapy
Androgen receptor
Atezolizumab
Bevacizumab
Breast cancer
Cabazitaxel